

Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook

<https://marketpublishers.com/r/HBA75C83942EN.html>

Date: November 2013

Pages: 0

Price: US\$ 7,495.00 (Single User License)

ID: HBA75C83942EN

Abstracts

The worldwide hepatitis C (HCV) market is forecast to grow from \$4.7 billion in 2012 to \$17.7 billion in 2017. The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more effective and tolerable pipeline agents.

Therapy Trends Consensus Outlook: Hepatitis C provides an in-depth analysis of the products players and events that will shape the future HCV market.

Therapy Trends Consensus Outlook: HIV includes the following comprehensive resources:

An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance

An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017

Updated reports and data analysis files delivered to your inbox after each significant market event.

Key Benefits

Therapy Trends Consensus Outlook: Hepatitis C provides:

Evaluate future sales forecasts and predicted market growth

Map your market parameters and chart commercial prospects

Assess market share by company and product

Tailor your strategic and investment focus based on the competition

Set proactive launch and branding strategies

Keep up with event-driven market data updates

Forecast analysis report and data model

The forecast analysis report component of Consensus Outlook: Hepatitis C delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Historical HCV sales from 2007–2012

Forecast HCV sales from 2013-2017

Key competitors and drug developers

Predicted product positioning

Current and late-stage pipeline drugs

Future event mapping to forecast data points

Comparative clinical trial results

FirstWord's HCV forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.

Market size

Product sales

Company forecasts

Company, brand, and drug class

Mechanism of action Future events

Event Assessments

Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event's occurrence.

Whether it's a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.

Methodology

For each Therapy Trends report, FirstWord analysts produce a data analysis module-a Consensus Outlook-which provides annual historical and forecast product-level sales data. Historical sales data is derived from company information, while the five-year (2012-2017) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections—produced either internally or by other third parties—can be assessed.

Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.

Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.

Contents

Market Overview

Hepatitis C Marketplace

Key Hepatitis C Developers

Hepatitis C Class Dynamics

Product Forecasts

Incivek (telaprevir; Vertex Tibotec/Mitsubishi Tanabe) forecast

Victralis (boceprevir; Merck) forecast

PegaSys (pegylated interferon-alpha; Roche) forecast

PegIntron (pegylated interferon-alpha; Merck) forecast

Sofosbuvir (GS-7977, Gilead) forecast

Abbott franchise (ABT-333/ABT-450/ABT-267; Abbott) forecast

Bristol-Myers Squibb franchise (daclatasvir/asunaprevir) forecast

Sovaprevir (ACH-1625; Achillion Pharmaceuticals) forecast

MK-5172 (Merck) forecast

Vaniprevir (MK-7009; Merck) forecast

Simeprevir (TMC435; Medivir/Tibotec) forecast

VX-222 (Vertex) forecast

I would like to order

Product name: Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook

Product link: <https://marketpublishers.com/r/HBA75C83942EN.html>

Price: US\$ 7,495.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HBA75C83942EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

